Waters Corp WAT
We take great care to ensure that the data presented and summarized in this overview for WATERS CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding WAT
View all-
Vanguard Group Inc Valley Forge, PA7.1MShares$2.63 Billion0.05% of portfolio
-
Black Rock Inc. New York, NY5.65MShares$2.1 Billion0.04% of portfolio
-
Terry Smith Fundsmith LLP | London, X03.63MShares$1.35 Billion5.85% of portfolio
-
Wealthfront Advisers LLC3.09MShares$1.14 Billion0.95% of portfolio
-
Alliancebernstein L.P. New York, NY2.65MShares$984 Million0.35% of portfolio
-
State Street Corp Boston, MA2.6MShares$964 Million0.04% of portfolio
-
Massachusetts Financial Services CO Boston, MA1.94MShares$720 Million0.24% of portfolio
-
Generation Investment Management LLP London, X01.53MShares$567 Million3.05% of portfolio
-
Geode Capital Management, LLC Boston, MA1.45MShares$538 Million0.04% of portfolio
-
Fundsmith Investment Services Ltd. Grande Riviere Noire, O41.22MShares$454 Million6.0% of portfolio
Latest Institutional Activity in WAT
Top Purchases
Top Sells
About WAT
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by life science, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.
Insider Transactions at WAT
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 01
2025
|
Jianqing Bennett SVP TA Instruments Division |
SELL
Payment of exercise price or tax liability
|
Direct |
786
-13.09%
|
$291,606
$371.79 P/Share
|
Mar 01
2025
|
Udit Batra President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,976
-16.86%
|
$1,846,096
$371.79 P/Share
|
Mar 01
2025
|
Amol Chaubal SVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,076
-16.7%
|
$399,196
$371.79 P/Share
|
Feb 05
2025
|
Amol Chaubal SVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,150
+24.3%
|
-
|
Feb 05
2025
|
Udit Batra President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
14,971
+20.7%
|
-
|
Feb 05
2025
|
Robert L Carpio Iii SVP, Waters Division |
BUY
Grant, award, or other acquisition
|
Direct |
543
+16.29%
|
-
|
Feb 05
2025
|
Jianqing Bennett SVP TA Instruments Division |
BUY
Grant, award, or other acquisition
|
Direct |
3,233
+20.99%
|
-
|
Jan 02
2025
|
Heather Knight Director |
BUY
Grant, award, or other acquisition
|
Direct |
319
+36.29%
|
-
|
Jan 02
2025
|
Wei Jiang Director |
BUY
Grant, award, or other acquisition
|
Direct |
319
+11.92%
|
-
|
Jan 02
2025
|
Mark P Vergnano Director |
BUY
Grant, award, or other acquisition
|
Direct |
319
+7.04%
|
-
|
Jan 02
2025
|
Pearl S Huang Director |
BUY
Grant, award, or other acquisition
|
Direct |
319
+9.77%
|
-
|
Jan 02
2025
|
Flemming Ornskov Director |
BUY
Grant, award, or other acquisition
|
Direct |
319
+6.45%
|
-
|
Jan 02
2025
|
Christopher A Kuebler Director |
BUY
Grant, award, or other acquisition
|
Direct |
319
+2.08%
|
-
|
Jan 02
2025
|
Richard H Fearon Director |
BUY
Grant, award, or other acquisition
|
Direct |
319
+13.92%
|
-
|
Jan 02
2025
|
Linda Baddour Director |
BUY
Grant, award, or other acquisition
|
Direct |
319
+11.05%
|
-
|
Jan 02
2025
|
Daniel J. Brennan Director |
BUY
Grant, award, or other acquisition
|
Direct |
319
+23.74%
|
-
|
Dec 31
2024
|
Wei Jiang Director |
BUY
Grant, award, or other acquisition
|
Direct |
80
+3.78%
|
-
|
Dec 31
2024
|
Heather Knight Director |
BUY
Grant, award, or other acquisition
|
Direct |
72
+23.0%
|
-
|
Dec 31
2024
|
Pearl S Huang Director |
BUY
Grant, award, or other acquisition
|
Direct |
83
+3.06%
|
-
|
Sep 30
2024
|
Heather Knight Director |
BUY
Grant, award, or other acquisition
|
Direct |
32
+16.0%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 28.7K shares |
---|---|
Open market or private purchase | 1K shares |
Exercise of conversion of derivative security | 4K shares |
Payment of exercise price or tax liability | 7.19K shares |
---|---|
Open market or private sale | 4K shares |